Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of “Moderate Buy” by Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $15.60.

Several equities research analysts have weighed in on the company. Wedbush started coverage on Kalaris Therapeutics in a research report on Thursday, May 14th. They issued an “outperform” rating and a $17.00 target price on the stock. Morgan Stanley began coverage on Kalaris Therapeutics in a report on Thursday, April 16th. They set an “overweight” rating and a $14.00 price target on the stock. Citizens Jmp cut their price objective on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. Wall Street Zen upgraded shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Wednesday, May 13th.

Institutional Investors Weigh In On Kalaris Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Kalaris Therapeutics during the fourth quarter valued at about $34,000. Barclays PLC bought a new stake in shares of Kalaris Therapeutics during the fourth quarter valued at about $51,000. Johnson Financial Group Inc. bought a new stake in shares of Kalaris Therapeutics during the third quarter valued at about $58,000. XTX Topco Ltd bought a new stake in shares of Kalaris Therapeutics during the second quarter valued at about $65,000. Finally, WealthTrust Asset Management LLC bought a new stake in shares of Kalaris Therapeutics during the first quarter valued at about $72,000. 66.05% of the stock is currently owned by institutional investors.

Kalaris Therapeutics Price Performance

Shares of NASDAQ KLRS opened at $5.12 on Friday. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $11.88. The business’s fifty day moving average price is $6.10 and its two-hundred day moving average price is $7.52. The firm has a market capitalization of $121.80 million, a PE ratio of -2.38 and a beta of 0.15.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.06. Equities research analysts expect that Kalaris Therapeutics will post -2.09 earnings per share for the current fiscal year.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.